Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises the founders and the current owners in connection with Altor’s investment in global fashion house Totême
Mandate

Vinge advises the founders and the current owners in connection with Altor’s investment in global fashion house Totême

May 21, 2021 M&A

Vinge advises the founders and other existing shareholders in connection with Altor Fund V’s investment in the global fashion house Totême. The founders will remain as majority shareholders and continue in their current roles in the development of Totême. Altor will support the founders and the company on its continued international growth journey.

Founded by Elin Kling and Karl Lindman in 2014 in New York City, Totême is a fast-growing fashion label in the modern luxury universe, widely known for their iconic uniforms. The company is headquartered in Stockholm with a strong Swedish heritage but with a true global presence. Sales are evenly split between Asia, North America and Europe, with a predominantly online presence via its own web shop and online retailers.

Vinge’s team consisted of Jonas Bergström, Karl Klackenberg and Hannah Kajlinger (M&A) as well as Viktoria Owetz Leyva (VDR Specialist).

 

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026